InVivo Therapeutics Hldgs Corp (fka NVIVQ)

[rru2s]

Unlikely to be lasting negativity from changing CEOs, as it was largely in-line with what investors appeared to desire, and secondly because shortsellers tried this one time before when the stock was at about $2.10 last winter, and they spun the fear of NVIV never getting HUD approval from the FDA. The stock dropped to $1.60 but only for a couple of days. Most importantly, NVIV DID deliver the goods and got full FDA approval for the biopolymer scaffold as a HUD/IDE, which is what the shorts tried to infer would never happen.

The start of patient trials is exactly the same dynamic - shorts want you to believe the whole company is going to fail based on poor execution and bad science, when in reality they have a top-notch, world class research team in charge, and have ALREADY been approved by FDA for the scaffold to be used in up to 4,000 patients per year, with the ability to charge money for each unit sold according to the cost of research and development and production. Uplisting will also happen, too, but only when the ducks are all aligned, but keep in mind they have already made some corrections since they announced their intent to uplist 3 months ago.